The Library
Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers
Tools
Pepper, Chris, Lin, Thet Thet, Pratt, Guy, Hewamana, Saman, Brennan, Paul , Hiller, Louise, Hills, R., Ward, Rachel, Starczynski, Jane, Austen, Belinda, Hooper, Laura, Stankovic, Tatjana and Fegan, Chris (2008) Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood, Vol.112 (No.9). pp. 3807-3817. doi:10.1182/blood-2008-05-157131 ISSN 0006-4971.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1182/blood-2008-05-157131
Abstract
Bcl-2 family proteins play a critical role in the regulation of apoptosis in chronic lymphocytic leukemia (CLL). However, their association with established prognostic markers is unknown. In this study, we analyzed the expression of Bcl-2, Bax, and Mcl-1 in 185 CLL patients and evaluated their relationship with other prognostic markers, in vitro sensitivity to fludarabine, and clinical outcome. Mcl-1 expression was significantly correlated with stage of disease (P <.001), lymphocyte doubling time (P =.01),V-H gene mutation status (P <.001), CD38 expression (P <.001), and ZAP-70 expression (P= .003). In addition, Mcl-1 and Mcl-1/Bax ratios showed strong correlations with in vitro resistance to fludarabine (P =.005 and P <.001, respectively). Furthermore, elevated Mcl-1 expression and Mcl-1/Bax ratios were predictive of time to first treatment in the whole cohort (P <.001 and P <.001, respectively) and in stage A patients only (P =.002 and P =.001, respectively). Taken together, our data show that Mcl-1 is a key controller of in vitro drug resistance and is an important regulator of disease progression and outcome in CLL. It therefore represents a promising therapeutic target in this incurable condition. The close correlation between Mcl-1 expression and VH gene mutation status, CD38 expression, and ZAP-70 expression offers a biologic explanation for their association with adverse prognosis. (Blood. 2008; 112:3807-3817)
Item Type: | Journal Article | ||||
---|---|---|---|---|---|
Subjects: | Q Science > QH Natural history > QH301 Biology R Medicine > RB Pathology R Medicine > RC Internal medicine |
||||
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||
Library of Congress Subject Headings (LCSH): | Lymphocytic leukemia -- Pathology, Apoptosis | ||||
Journal or Publication Title: | Blood | ||||
Publisher: | American Society of Hematology | ||||
ISSN: | 0006-4971 | ||||
Official Date: | 1 November 2008 | ||||
Dates: |
|
||||
Volume: | Vol.112 | ||||
Number: | No.9 | ||||
Number of Pages: | 11 | ||||
Page Range: | pp. 3807-3817 | ||||
DOI: | 10.1182/blood-2008-05-157131 | ||||
Status: | Peer Reviewed | ||||
Publication Status: | Published | ||||
Access rights to Published version: | Restricted or Subscription Access | ||||
Funder: | Leukaemia Research UK (LRUK), Leukaemia Research Appeal for Wales, Welsh Bone Marrow Transplant Research Fund |
Data sourced from Thomson Reuters' Web of Knowledge
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |